A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study

BMC Cancer

Table 6 Bioclinical features of the tumours of the validation set forming the molecular subgroups as defined by the Chi2 analysis

Subgroup	Number of tumours	Hormonal status		Age	Tumour size	Histological grade (SBR)			Clinical outcome
	n	% ER+	% ER-	% <50 years	% <20 mm	% SBRI	% SBRII	% SBRIII	% recurrence
SG1	7	100	0	71	43	0	71	29	43
SG2	1	100	0	100	100	0	0	100	0
SG3/4	28	93	7	39	46	18	39	43	46
SG6	18	89	11	67	78	22	39	39	28
SG7	11	82	18	73	82	27	9	64	27
SG9	14	57	43	64	36	0	0	100	57
SG10	30	30	70	70	40	3	17	80	53
Overall cohort	109	70	30	61	52	12	27	61	44

ISSN: 1471-2407